



OFFICE OF THE DEPARTMENT OF DEFENSE COORDINATOR
FOR DRUG ENFORCEMENT POLICY AND SUPPORT

1510 DEFENSE PENTAGON
WASHINGTON DC 20301-1510

10 JUN 1998

MEMORANDUM FOR ASSISTANT SECRETARY OF THE ARMY (M&RA)
ASSISTANT SECRETARY OF THE NAVY (M&RA)
DEPUTY ASSISTANT SECRETARY OF THE AIR FORCE (FM&P)
DIRECTOR, COUNTERDRUG DIRECTORATE, NATIONAL
GUARD BUREAU
DIRECTOR, ARMED FORCES INSTITUTE OF PATHOLOGY

SUBJECT: LSD Drug Screening Analysis

Effective July 1, 1998, laboratories possessing DoD certification for lysergic acid diethylamide (LSD) drug screening may transition from radioimmunoassay (RIA) to the immunoassay (IA) technology. Laboratory operating procedures (LOP) manuals must be modified to reflect the transition to the IA procedure for LSD testing.

Procurement of the LSD immunoassay reagent will be in accordance with current contract requirement. In addition, the LSD immunoassay reagent will be used in accordance with published manufacturer's specifications for the automated instrumentation within the laboratory.

Nothing in this memorandum abrogates the responsibilities of the laboratory supervisors and staff for documenting and maintaining the scientific and forensic integrity of the military drug testing program.

Robert J. Newberry

Robert J. Newberry
Acting Deputy Assistant Secretary of Defense for
Drug Enforcement Policy and Support

CC:
Service Drug Program Managers
DoD Military Drug Laboratories

